BRPI0810661A2 - [2,6] naftiridinas úteis como inibidoras de quinase proteica. - Google Patents

[2,6] naftiridinas úteis como inibidoras de quinase proteica.

Info

Publication number
BRPI0810661A2
BRPI0810661A2 BRPI0810661-4A BRPI0810661A BRPI0810661A2 BR PI0810661 A2 BRPI0810661 A2 BR PI0810661A2 BR PI0810661 A BRPI0810661 A BR PI0810661A BR PI0810661 A2 BRPI0810661 A2 BR PI0810661A2
Authority
BR
Brazil
Prior art keywords
protein kinase
kinase inhibitors
inhibitors
naphthyridines
useful
Prior art date
Application number
BRPI0810661-4A
Other languages
English (en)
Inventor
Rolf Dobler Markus
Charles Francis Jewell, Jr.
Meredith Erik
G. Monovich Lauren
Siska Sarah
Von Matt Anette
Van Eis Maurice
Yoon Taeyoung
Gaul Christoph
Paul Capparelli Michael
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0810661A2 publication Critical patent/BRPI0810661A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

[2, 6 ] naftiridinas úteis como inibidoras de quinase proteica a presente invenção refere-se a um composto de fórmula i : o dito composto é inibidor de subconjuntos seletivos de quinases pertencentes à família agc ou calmodulina quinase, como por exemplo mark1/2/3, pkd-1/2/3, pkn-1/2, cdk-9, camkii, rock-i/ii, inibidores da fosforilação de histona deacetilase (hdac) ou inibidores de outras quinases. finalmente, a presente invenção também oferece uma composição farmacêutica.
BRPI0810661-4A 2007-04-06 2008-04-04 [2,6] naftiridinas úteis como inibidoras de quinase proteica. BRPI0810661A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91051907P 2007-04-06 2007-04-06
US60/910,519 2007-04-06
PCT/EP2008/054105 WO2008122615A1 (en) 2007-04-06 2008-04-04 [2, 6] naphthyridines useful as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0810661A2 true BRPI0810661A2 (pt) 2019-04-30

Family

ID=39590973

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810661-4A BRPI0810661A2 (pt) 2007-04-06 2008-04-04 [2,6] naftiridinas úteis como inibidoras de quinase proteica.

Country Status (16)

Country Link
US (1) US20120142685A1 (pt)
EP (1) EP2144909B1 (pt)
JP (1) JP2010523530A (pt)
KR (1) KR20100016291A (pt)
CN (1) CN101679418A (pt)
AT (1) ATE502940T1 (pt)
AU (1) AU2008235456B2 (pt)
BR (1) BRPI0810661A2 (pt)
CA (1) CA2682340A1 (pt)
DE (1) DE602008005729D1 (pt)
EA (1) EA016108B1 (pt)
ES (1) ES2363831T3 (pt)
MX (1) MX2009010697A (pt)
PL (1) PL2144909T3 (pt)
PT (1) PT2144909E (pt)
WO (1) WO2008122615A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522865A (ja) * 2008-06-13 2011-08-04 ノバルティス アーゲー Ｉａ心不全および癌の治療に有用なプロテインキナーゼｄ阻害剤としての２，４’−ビピリジニル化合物
PH12012501556A1 (en) * 2009-12-30 2012-10-22 Arqule Inc Substituted naphthalenyl-pyrimidine compounds
EP2495244A1 (en) * 2011-03-02 2012-09-05 NovaSaid AB Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors
ES2761587T3 (es) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
EP4302834A3 (en) 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
JP7361693B2 (ja) 2017-12-15 2023-10-16 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての多環式化合物
WO2022005943A2 (en) 2020-06-30 2022-01-06 Genentech, Inc. Processes for making serd tricyclic compounds having a substituted phenyl or pyridinyl moiety
KR20240016977A (ko) * 2021-06-04 2024-02-06 제넨테크, 인크. 2,8-디아자스피로[4.5]데칸 화합물
AU2022412837A1 (en) * 2021-12-16 2024-06-13 Teijin Pharma Limited Cdk9 inhibitor and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928367A (en) * 1969-04-14 1975-12-23 Schering Corp 1-Amino naphthyridines
CA2579406A1 (en) * 2004-09-21 2006-03-30 F.Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as protein kinase inhibitors
EP2144908A1 (en) * 2007-04-06 2010-01-20 Novartis Ag 2, 6-naphthyridine derivatives as protein kinase modulators

Also Published As

Publication number Publication date
WO2008122615A1 (en) 2008-10-16
EP2144909B1 (en) 2011-03-23
ATE502940T1 (de) 2011-04-15
AU2008235456A1 (en) 2008-10-16
CA2682340A1 (en) 2008-10-16
PL2144909T3 (pl) 2011-08-31
DE602008005729D1 (en) 2011-05-05
EA016108B1 (ru) 2012-02-28
EP2144909A1 (en) 2010-01-20
CN101679418A (zh) 2010-03-24
US20120142685A1 (en) 2012-06-07
ES2363831T3 (es) 2011-08-17
EA200901325A1 (ru) 2010-04-30
AU2008235456B2 (en) 2011-12-08
KR20100016291A (ko) 2010-02-12
MX2009010697A (es) 2009-12-11
JP2010523530A (ja) 2010-07-15
PT2144909E (pt) 2011-06-29

Similar Documents

Publication Publication Date Title
BRPI0810661A2 (pt) [2,6] naftiridinas úteis como inibidoras de quinase proteica.
BRPI0613429A2 (pt) inibidores de histona desacetilase
BRPI0720525B8 (pt) inibidores de mapk/erk quinase
WO2010009139A3 (en) Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
WO2010009155A3 (en) Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
BR112013016595A2 (pt) inibidores de neprilisina
TN2010000131A1 (en) Polo-like kinase inhibitors
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
EA200970156A1 (ru) Пиридизиноновые производные
ATE479687T1 (de) Kinaseinhibitoren
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
EA200700138A1 (ru) Замещённые индолильные алкиламинопроизводные в качестве новых ингибиторов гистондеацетилазы
BR112013000868A2 (pt) derivados de pirazol [1,5a] e tieno [3,2b] pirimidina como modulares de irak4
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
EA200401197A1 (ru) Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
BR112012013508A2 (pt) pirazolopirimidinas e heterociclos relacionados como inibidores de ck2
BRPI0809542A8 (pt) Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
TW201613938A (en) Selective inhibitors for protein kinases, a pharmaceutical composition and an use thereof
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
EA200700143A1 (ru) Производные замещенного пропенилпиперазина в качестве новых ингибиторов гистондеацетилазы

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A, 9A, 10A E 11A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.